Zymeworks Inc. (NYSE:ZYME) Shares Acquired by SG Americas Securities LLC

SG Americas Securities LLC lifted its stake in shares of Zymeworks Inc. (NYSE:ZYME) by 9.9% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 27,439 shares of the company’s stock after buying an additional 2,481 shares during the quarter. SG Americas Securities LLC’s holdings in Zymeworks were worth $285,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Gladius Capital Management LP boosted its holdings in Zymeworks by 36.5% in the third quarter. Gladius Capital Management LP now owns 3,940 shares of the company’s stock valued at $25,000 after purchasing an additional 1,053 shares in the last quarter. Public Employees Retirement System of Ohio acquired a new position in Zymeworks in the second quarter valued at approximately $35,000. Ameritas Investment Partners Inc. acquired a new position in Zymeworks in the second quarter valued at approximately $38,000. Quantbot Technologies LP acquired a new position in Zymeworks in the first quarter valued at approximately $42,000. Finally, Coppell Advisory Solutions LLC acquired a new position in Zymeworks in the second quarter valued at approximately $48,000. 92.89% of the stock is owned by institutional investors and hedge funds.

Zymeworks Stock Down 2.7 %

Shares of ZYME opened at $9.36 on Wednesday. The stock has a 50 day moving average price of $11.10 and a 200 day moving average price of $9.44. The company has a market capitalization of $660.54 million, a price-to-earnings ratio of -5.38 and a beta of 1.14. Zymeworks Inc. has a 52-week low of $6.01 and a 52-week high of $13.14.

Zymeworks (NYSE:ZYME) last announced its quarterly earnings results on Wednesday, March 6th. The company reported ($0.20) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.39) by $0.19. The firm had revenue of $16.93 million during the quarter, compared to the consensus estimate of $18.32 million. Zymeworks had a negative return on equity of 26.20% and a negative net margin of 156.12%. On average, equities analysts anticipate that Zymeworks Inc. will post -1.04 EPS for the current fiscal year.

Zymeworks Profile

Zymeworks Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors.